William J. Abrams - 16 Dec 2025 Form 4 Insider Report for Medline Inc. (MDLN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Mar 2026, 16:30:28 UTC
Next SEC filing
17 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Fritz, Attorney-in-Fact

Key filing fact

William J. Abrams filed Form 4 for Medline Inc. (MDLN) on 06 Mar 2026.

Key facts

  • This page summarizes William J. Abrams's Form 4 filing for Medline Inc. (MDLN).
  • 9 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 06 Mar 2026, 16:30.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002061059 Primary reporting owner

Abrams William J

Relationship
Title: Executive Vice President, Supply Chain Solutions
Address
C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
Signature
/s/ Nicole Fritz, Attorney-in-Fact
Signature date
06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDLN transaction

Class B Common Stock

Award

Transaction value
Shares
+495,680
Change %
Price
Shares after
495,680
Date
16 Dec 2025
Ownership
Direct
Footnotes
F1, F2
MDLN transaction

Class B Common Stock

Award

Transaction value
Shares
+30,655
Change %
Price
Shares after
30,655
Date
16 Dec 2025
Ownership
See Footnote
Footnotes
F1, F2, F3
MDLN transaction

Class A Common Stock

Award

Transaction value
Shares
+17,854
Change %
Price
$0.000000*
Shares after
17,854
Date
05 Mar 2026
Ownership
Direct
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDLN transaction Derivative

Common Units of Medline Holdings, LP

Award

Transaction value
Shares
+495,680
Change %
Price
Shares after
495,680
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
495,680
Exercise price
Footnotes
F1, F5
MDLN transaction Derivative

Common Units of Medline Holdings, LP

Award

Transaction value
Shares
+30,655
Change %
Price
Shares after
30,655
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
30,655
Exercise price
Footnotes
F1, F3, F5
MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+1,129,447
Change %
Price
Shares after
1,129,447
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
1,129,447
Exercise price
$15.42
Footnotes
F1, F6, F7, F8
MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+170,204
Change %
Price
Shares after
170,204
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
170,204
Exercise price
$15.23
Footnotes
F1, F6, F7, F9
MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+91,078
Change %
Price
Shares after
91,078
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
91,078
Exercise price
$19.01
Footnotes
F1, F6, F7, F10
MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+97,531
Change %
Price
Shares after
97,531
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
97,531
Exercise price
$27.68
Footnotes
F1, F6, F7, F11
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 11 footnotes

Footnote F1

These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

Footnote F2

Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.

Footnote F3

These securities are held by a trust, of which the Reporting Person serves as a trustee.

Footnote F4

Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.

Footnote F5

Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.

Footnote F6

Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.

Footnote F7

(Continued from Footnote 6 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.

Footnote F8

80% of these Incentive Units have vested, and the remaining 20% vest on October 21, 2026.

Footnote F9

40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.

Footnote F10

20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.

Footnote F11

These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

SEC remarks

Title: Executive Vice President, Supply Chain Solutions

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .